Skip to content
PoliticalRepoPoliticalRepo

United States · Bill · HR

H.R. 19 (117th)

Lower Costs, More Cures Act of 2021

referredUnited States· United States Congress· EN

Introduced

21 April 2021

Last action

19 October 2021 · Referred

Status

Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.

Sponsors

Rep. McMorris Rodgers, Cathy [R-WA-5], Rep. Brady, Kevin [R-TX-8], Rep. Foxx, Virginia [R-NC-5], Rep. Guthrie, Brett [R-KY-2], Rep. Nunes, Devin [R-CA-22], Rep. Allen, Rick W. [R-GA-12], Rep. Smucker, Lloyd [R-PA-11], Rep. Johnson, Dusty [R-SD-At Large], Rep. Hudson, Richard [R-NC-8], Rep. Schweikert, David [R-AZ-1], Rep. Barr, Andy [R-KY-6], Rep. Estes, Ron [R-KS-4], Rep. Carter, Earl L. "Buddy" [R-GA-1], Rep. Latta, Robert E. [R-OH-5], Rep. Bilirakis, Gus M. [R-FL-12], Rep. McCarthy, Kevin [R-CA-22], Rep. Walorski, Jackie [R-IN-2], Rep. Pence, Greg [R-IN-6], Rep. Rice, Tom [R-SC-7], Rep. Carter, John R. [R-TX-31], Rep. Nehls, Troy E. [R-TX-22], Rep. Ferguson, A. Drew, IV [R-GA-3], Rep. Smith, Jason [R-MO-8], Rep. Griffith, H. Morgan [R-VA-9], Rep. Buchanan, Vern [R-FL-16], Rep. Wenstrup, Brad R. [R-OH-2], Sen. Curtis, John R. [R-UT], Rep. LaHood, Darin [R-IL-16], Rep. Jackson, Ronny [R-TX-13], Rep. Reed, Tom [R-NY-23], Rep. Van Duyne, Beth [R-TX-24], Madison Cawthorn, Rep. Reschenthaler, Guy [R-PA-14], Rep. Tenney, Claudia [R-NY-24], Rep. Burchett, Tim [R-TN-2], Rep. Davis, Rodney [R-IL-13], Rep. Armstrong, Kelly [R-ND-At Large], Rep. Bucshon, Larry [R-IN-8], Rep. Norman, Ralph [R-SC-5], Rep. McKinley, David B. [R-WV-1], Rep. Hern, Kevin [R-OK-1], Rep. Wagner, Ann [R-MO-2], Rep. Williams, Roger [R-TX-25], Rep. Burgess, Michael C. [R-TX-26], Rep. Harshbarger, Diana [R-TN-1], Rep. Meuser, Daniel [R-PA-9], Rep. Joyce, John [R-PA-13], Rep. Bacon, Don [R-NE-2]

Subjects

Healthcare

Source updated

7 April 2025

Healthcare

Official sourceDownload fileView documentsShare

Summary

Lower Costs, More Cures Act of 2021 This bill establishes and modifies several programs and requirements to address prescription drug prices. The bill modifies provisions under Medicare and Medicaid relating to prescription drug coverage and price transparency. Among other changes, the bill requires the Centers for Medicare & Medicaid Services to publish certain information, as reported by pharmacy benefit managers (PBMs), relating to generic dispensing rates, drug discounts and rebates, and payments between PBMs, health plans, and pharmacies; caps annual out-of-pocket spending under the Medicare prescription drug benefit; allows prescription drug plan sponsors under the Medicare prescription drug benefit to offer additional plans in a region; requires pass-through pricing models, and prohibits spread-pricing, for payment arrangements with PBMs under Medicaid; and allows states to include in the Medicaid Drug Rebate Program covered outpatient drugs that are provided as part of physician or outpatient hospital services. The bill also generally modifies other provisions relating to the regulation and costs of generic and brand-name drugs. Among other changes, the bill prohibits the manufacturer of a brand-name, generic, or biosimilar drug from entering into certain agreements to resolve or settle a patent infringement claim in connection with the sale of a drug or biological product; permanently allows high deductible health plans to waive deductibles for insulin and associated products; and establishes the position of Chief Pharmaceutical Negotiator in the Office of the U.S. Trade Representative.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

  1. 21 April 2021

    Referred

    Referred to the Subcommittee on Health.

    Source: Committee

  2. 21 April 2021

    Introduced

    Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

    Source: IntroReferral

  3. 21 April 2021

    Introduced

    Introduced in House

    Source: IntroReferral

  4. 21 April 2021

    Introduced

    Introduced in House

    Source: IntroReferral

  5. 22 April 2021

    Referred

    Referred to the Subcommittee on Health.

    Source: Committee

  6. 19 October 2021

    Referred

    Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.

    Source: Committee

Votes

No vote records are attached yet.

Versions

Documents

3 official files

Introduced in House (text)

View fileDownload file

This file cannot be previewed here. Use View or Download.

Leesvertaling

Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Introduced in House (text)

    Introduced in House · EN · 21 April 2021

    ViewDownloadOpen at official source

  • Introduced in House (PDF)

    Introduced in House · EN · 21 April 2021

    ViewDownloadOpen at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Introduced in House

    summary · EN · 21 April 2021

    Open at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

Sponsors

Showing 48 of 137 sponsors and actors.

Related records

Sources

PoliticalRepo is an index and interpretation layer, not the authoritative legal source.